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ABSTRACT
Objectives: To describe current disease-modifying
antirheumatic drugs (DMARDs) prescription in
rheumatoid arthritis (RA) with reference to best
practice and to identify temporal and regional trends in
the UK.
Design: Descriptive, register-based cohort study.
Participants: Permanently registered patients aged
≥18 years with a recorded diagnosis of RA between 1
January 1995 and 31 March 2010 and matched
controls. Participants with RA were identified through
screening of all patients in the General Practice
Research Database (GPRD) with a clinical or referral
record for RA and at least 1 day of follow-up.
Setting: 639 general practices in the UK supplying
data to the GPRD.
Main outcome measures: Medication prescribing
between 3 and 12 months of RA diagnosis by region
and time period (1995–1999, 2000–2005 and 2006–
April 2010).
Results: Of the 35 911 patients in the full RA cohort,
15 259 patients (42%) had incident RA. Analysis of
prescribing in incident RA patients demonstrated that
between 1995 (baseline) and 2010 there was a
substantial increase in DMARD, and specifically
methotrexate, prescribing across all regions with a less
marked increase in combination DMARD prescribing.
Taking 12-month prescribing as a snapshot: DMARD
prescribing was 19–49% at baseline increasing to
45–74% by 2006–April 2010; methotrexate prescribing
was 4–16% at baseline increasing to 32–60%;
combination DMARD prescribing was 0–8% at baseline
increasing to 3–17%. However, there was marked
regional variation in the proportion of RA patients
receiving DMARD regardless of time period.
Conclusions: There has been a substantial increase in
prescribing of DMARDs for RA since 1995; however,
regional variation persists across the UK with relative
undertreatment, according to established best practice.
Improved implementation of evidence-based best
clinical practice to facilitate removal of treatment
variation is warranted. This may occur as a result of
the implementation of published national guidance.
ARTICLE SUMMARY
Article focus
▪ Over recent years there have been fundamental
changes in the approach to the treatment of
rheumatoid arthritis (RA) with a move towards
early and more aggressive treatment.
▪ Disease-modifying antirheumatic drugs
(DMARDs) are effective in the treatment of RA
and their early use is recommended in national
and international clinical guidelines and
recommendations.
▪ We describe both temporal and regional trends
in DMARD therapy for RA throughout the UK
over a 15-year period and reveal whether the
latest knowledge on how RA should be treated
has been translated into actual clinical practice.
Key messages
▪ There has been a substantial increase in DMARD
prescription for RA and an increase in the pro-
portion of patients prescribed DMARD earlier in
the course of their disease between 1995 and
2010.
▪ However, RA remains relatively undertreated
according to best practice and published national
guidelines, and regional variation persists.
▪ There is a need to optimise dissemination and
implementation of high-quality clinical guidelines
and to monitor implementation.
Strengths and limitations of this study
▪ One of the strengths of the study was the size of
the study population with 15 259 patients with
incident RA and of the long-term follow-up of
these patients (mean 5.5 years but up to
15.3 years for some patients). Another is the
generalisability of the General Practice Research
Database (GPRD) database from which our data
were obtained.
▪ The coding of the diagnosis of RA is a potential
limitation; however, GPRD has been validated in
previous studies and in this study by the obser-
vation of similar demographics for DMARD
versus non-DMARD users.
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INTRODUCTION
Rheumatoid arthritis (RA) is a chronic, systemic, auto-
immune disease, the most common form of chronic
joint inﬂammation1 and is associated with substantial
long-term morbidity, mortality and healthcare costs.2 A
recent report from the National Audit Ofﬁce estimates
that around 580 000 people have RA in England and
that 26 000 patients are diagnosed with RA each year.3
RA can have a profound effect on patients through the
physical manifestations of the disease, associated compli-
cations and impact on health-related quality of life
(HRQOL).4 Disease-modifying antirheumatic drugs
(DMARDs), used either as monotherapy or in combin-
ation, can control disease activity, reduce joint erosions,5
improve quality of life6 and also reduce the cardiovascu-
lar morbidity associated with RA.7
Over recent years, there have been fundamental
changes in the approach to treatment of RA with the
availability of newer therapies and a move towards early
and more aggressive treatment.8 A recent meta-analysis
including data from 70 trials, demonstrates that aggres-
sive treatment with combination DMARDs is able to
reduce structural joint damage.9 DMARDs have a critical
role in the management of RA and are central to both
European recommendations8 and UK guidance.10
Issued in February 2009, National Institute for Health
and Clinical Excellence (NICE) clinical guidelines for
the treatment of RA recommend a combination of
DMARDs (including methotrexate and at least one
other DMARD, plus short-term glucocorticoids) as ﬁrst-
line treatment ideally within 3 months of symptom onset
for people with recently diagnosed active RA.10 The
NICE guidance serves as an example of best practice
although its publication in 2009 preclude us from deter-
mining accurately whether its recommendations have
been taken up in this study.
Much information regarding the use of DMARDs is
from published experience within the tertiary care
setting; however, it is unclear as to how well this reﬂects
routine practice in secondary and primary care settings
across the UK. Despite the demonstrated efﬁcacy of
DMARDs, data from over 34 000 primary care records
collected between 1987 and 2002 indicate that only half
of patients diagnosed with RA receive DMARD
therapy.11 The UK General Practice Research Database
(GPRD) is an electronic database of primary care
medical records. GPRD contains data on over 8% of the
population and has data on over 11 million individuals
(cumulative) with over ﬁve million currently active.11 12
The GPRD has been used in several studies and the val-
idity of an RA diagnosis in GPRD appears to be high for
patients with speciﬁc characteristics when using the
American College of Rheumatology (ACR) diagnostic
criteria as the standard.12 13 All patients in the UK will
be seen by a primary care physician or general practi-
tioner (GP) in addition to any secondary care physician
needed for care of a speciﬁc illness. Although indivi-
duals with RA were recruited to the GPRD by a GP the
validation studies described show that a rheumatologist
in secondary care will also have seen the vast majority of
individuals.12 The objectives of this study were to
provide an updated view of current DMARD prescribing
in RA with reference to best practice, to describe both
temporal and regional trends in DMARD therapy for RA
throughout the UK over a 15-year period, and to assess
whether the latest knowledge on how RA should be
treated has been translated into actual clinical practice.
METHODS
Data source
We obtained data for this study from the GPRD which
collates the computerised medical records of GPs. The
data recorded in the GPRD include demographic infor-
mation, prescription details, clinical events, preventive
care provided, specialist referrals, hospital admissions
and major outcomes. The GPRD contains the complete
anonymised patient medical records from GPs who use
the system from In Practice Systems (a software package
used for patient medical records) and who agree to
adhere to ‘Recording Guidelines’ that are subject to
detailed quality control checks of data at both practice
and individual patient levels.
Study design and population
We conducted a descriptive, cohort study in perman-
ently registered patients aged 18 years and over with a
recorded diagnosis of RA between 1 January 1995 and
31 March 2010. We identiﬁed our study population
through screening of all patients in the GPRD
(n=11 480 996); who had a clinical or referral record for
RA (n=63 238); with a record on or after 1 January 1995
(n=45 057); where this record was on or after the start of
follow-up (latest of patient registration or practice
up-to-standard (UTS) date; n=36 567); who were aged at
least 18 at this date (n=36 035); and who had at least
1 day of follow-up (n=35 911). We used the same Read
codes as in the previous RA validation study.12
The period of follow-up was from the date of ﬁrst RA
record up (ie, index date) to the date of censoring (ie,
latest GPRD data collection, patient’s transfer out of the
practice or patient’s death, whichever date came ﬁrst).
The study population included patients with a record of
RA prior to start of GPRD data collection (ie, prevalent
cases) and also RA patients with a ﬁrst-ever record of RA
at least 1 year after start of GPRD data collection (ie,
incident cases). Each RA patient was matched by age,
gender and practice to three patients without a record
of inﬂammatory disease (listed in appendix 1).
Analysis of utilisation characteristics
We conducted an analysis to describe the exposure char-
acteristics of incident RA patients from index date. We
measured the prevalence of the use of different medica-
tions stratiﬁed by age at diagnosis (at date of ﬁrst-ever
record of RA), age at time of measurement, sex,
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calendar year and strategic health authority. We deter-
mined the prevalence of medication use by evaluating
GP prescribing in the 6 months before the index date of
the following DMARDS: methotrexate; sulphasalazine;
hydroxychloroquine; gold (sodium aurothiomalate); aur-
anoﬁn; penicillamine; leﬂunomide; azathioprine; ciclos-
porin and cyclophosomide. Of note, GPRD captures
information on all prescriptions issued both acute and
repeat, along with dosage instructions.
RESULTS
Baseline characteristics
The full cohort included both incident and prevalent
RA cases and comprised a total of 35 911 patients. RA
patients and matched controls were well balanced in
terms of age, gender and socioeconomic status.
However, there was a higher prevalence of smokers and
a lower prevalence of drinkers among RA patients. Of
the 35 911 patients in the full RA cohort, a subgroup of
15 259 patients (42%) had an incident RA. With regard
to treatment, there was a 10-fold increase in prescribing
of prednisolone for incident RA patients versus matched
controls and a ninefold increase in prescribing of non-
steroidal anti-inﬂammatory drugs in the 6 months prior
to diagnosis.
Prescription practice by region and time period for
incident patients
General trends
The data were analysed to assess the proportion of inci-
dent RA patients prescribed either DMARD, methotrex-
ate or combination DMARD within 3, 6 or 12 months of
diagnosis according to geographic region and according
to time period (1995–1999, 2000–2005 and 2006–April
2010; appendix 2). In general, the data indicate that
across all regions and within each time period, the pro-
portion of patients prescribed DMARDs including
methotrexate increased between 3 and 12 months.
However, increases in the proportion of patients pre-
scribed combination DMARDs were less marked with
either no or little increase between 3–6 and 6–12 months
but a modest overall increase between 3 and 12 months.
Temporal change in medication prescribing
In order to provide a snapshot of change in DMARD
usage over time, the data were analysed to assess the pro-
portion of patients prescribed either any DMARD,
methotrexate or any combination of DMARDs within
12 months according to time period (1995–1999, 2000–
2005 and 2006–April 2010; table 1). There was a substan-
tial increase in 12-month prescribing of DMARD (from
36.9% to 60.1%), methotrexate (from 11.6% to 40.7%)
and combination DMARD (from 0.9% to 9.1%) over
the 15-year time period. Analysis of regional data
demonstrated an increase in the proportion of patients
prescribed DMARDs at 12 months across all regions
during the 15-year time period (ﬁgure 1). At baseline
(1995–1999) between 19.29% (East Midlands) and
49.06% (Northern Ireland) of patients were prescribed
DMARDs at 12 months; by 2006–April 2010 the rate of
prescribing had increased from between 45.32%
(London) and 73.6% (Scotland). A general trend for
increased prescription of DMARDs/methotrexate
between 3 and 12 months was also evident across all
regions. Of note, combination DMARDs tended to be
prescribed after 3 months with increasing prescription
between 6 and 12 months and between 1995 and April
2010 across all regions (appendix 2).
Regional variation
Analysis of data focusing on prescribing of DMARDs at
12 months demonstrates substantial regional variation in
DMARD prescribing regardless of time period (ﬁgure 1).
Regional variation in DMARD prescribing at 12 months
ranged from 19.29% to 49.06% between 1995 and 1999;
from 36.09% to 60.17% between 2000 and 2005 and from
45.32% to 73.6% between 2006 and April 2010. The
regional difference in the proportion of patients pre-
scribed DMARD at 12 months ranged from 24% to 30%
within each time period. Prescribing patterns of metho-
trexate and combination DMARDs also varied from
region to region regardless of time period (appendix 2).
Time from diagnosis to treatment
The data for incident patients with UTS data of 5 years
were analysed to evaluate time from diagnosis to treat-
ment with either DMARD and/or methotrexate. For
5513 patients prescribed a DMARD, the median time
from diagnosis to treatment was 50 days (IQR 0–1826);
for 3754 patients prescribed methotrexate, the median
time from diagnosis to treatment was 119 days (IQR
0–1826); while for 1310 patients prescribed combination
DMARD the median time from diagnosis to treatment
was 560 days (IQR 0–1826).
DISCUSSION
We have demonstrated that between 1995 and 2010
there was a substantial increase in DMARD, methotrex-
ate and combination DMARD prescribing across all
regions. In this 15-year period, 12-month prescribing of
DMARD almost doubled rising from 36.9% to 60.1%;
12-month prescribing of methotrexate quadrupled from
11.6% to 40.7% and 12-month prescribing of combin-
ation DMARD showed a 10-fold increase from 0.9% to
9.0%. However, some 40% of patients were not receiving
DMARD at 12 months despite national clinical guide-
lines recommending this therapy within 3 months of
diagnosis10 indicating a relative undertreatment of RA.
In addition, the marked regional variation in the pre-
scription of DMARDs within the UK persists and has not
decreased with time. To our knowledge, this is the ﬁrst
time that data on the use of DMARDs over this time
period has been examined in a large RA population in
the UK.
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Clinical implications
Several studies indicate that appropriate and timely
use of DMARDS and biologics for management of RA
can improve outcomes such as mortality risk and
HRQOL.14– 17 However, previous studies indicate
that many patients receive insufﬁcient treatment18 and
that there is variation in practice in the management of
RA.3 Our current data conﬁrm the signiﬁcant regional
variation both in the timing of DMARD or methotrexate
therapy and in the proportion of patients diagnosed
with RA receiving these therapies at speciﬁc time points.
Based on the latest data from 2006 to April 2010 for
regions in England (ie, excluding Wales, Scotland and
Northern Ireland), the proportion of RA patients receiv-
ing DMARDs at 12 months between 2006 and April 2010
ranges from 45.32% (London) to 66.83% (South
Central). In addition, the proportion of RA patients in
England receiving methotrexate at 12 months in this
latest time period ranges from 32.11% (North East) to
51.62% (South Central); at best two-thirds of RA patients
in England are being prescribed DMARDs and approxi-
mately one-half of RA patients in England are being pre-
scribed methotrexate by 12 months (appendix 2).
The underlying reasons for this variation are not clear
but could be due to several factors such as differences in
RA health spend or differences in implementation and
sharing of best practice. With the devolution of the
National Health Service in 1999, differences in health
services management and delivery exist between
England, Scotland, Wales and Northern Ireland.
Interestingly, our data indicate that Scotland and
Northern Ireland have the highest proportion of RA
patients prescribed DMARDs at 12 months (73.6% and
70.14%, respectively) and Northern Ireland the highest
proportion of patients prescribed methotrexate at
12 months (60.42%; 34.78% in Scotland). This may
suggest that there are lessons to be learned from regions
which demonstrate good practice, possibly through
understanding the impact of different networks, inter-
action and communication and the impact of different
health spend priorities. In addition, it would be interest-
ing to examine if regions with more aggressive use of
DMARDs may use more or less biological therapies. Of
note, there is as yet no benchmark deﬁning the propor-
tion of RA patients who should be prescribed DMARDs.
These drugs are not suitable for all RA patients for
example those with contraindications and women trying
to conceive. Therefore the ‘ideal’ would be less than
100% of patients and possibly around 80% seems a real-
istic estimate of the proportion of RA patients eligible
for DMARD therapy.
Several reports emphasise the importance of early and
appropriate intervention in RA to optimise patient out-
comes.10 19 A meta-analysis assessing the long-term
impact of early treatment on radiographic progression
in RA which included 1133 patients identiﬁed a critical
period for the initiation of RA therapy, a ‘therapeutic
window of opportunity’ early in the course of RA which
was associated with durable beneﬁt in radiographic pro-
gression for a period of up to 5 years. In this analysis,
there was a 33% reduction in long-term progression
rates in patients receiving early therapy for their disease
compared with those treated later.20 Importantly, sub-
optimal treatment can lead to joint damage necessitat-
ing surgery (with the associated resource implications),
and to a higher mortality risk from cardiovascular
disease, a risk which can be mitigated with appropriate
and timely methotrexate treatment.7
In our study, median time from diagnosis to treatment
with DMARD, methotrexate or combination DMARD
was 50, 119 and 560 days, respectively. This compares
with NICE clinical guideline recommendations for com-
bination DMARD treatment (including methotrexate)
to be used as ﬁrst-line therapy within 3 months of the
onset of persistent symptoms.10 Our ﬁndings indicate
that RA patients who do receive methotrexate have it
prescribed a median 4 months after diagnosis. Prior to
diagnosis many patients in our study were already receiv-
ing treatment or therapies that may ameliorate the symp-
toms of RA (appendix 3): this may further delay
treatment as RA symptoms are masked though damage
continues and can impact on outcomes. Given the likely
delay between symptom onset and diagnosis, the time
from symptom onset to methotrexate is probably greater
than 4 months. Furthermore, it should be noted that
during the most recent time period (2006–April 2010)
by 12 months at best only half of diagnosed RA patients
were prescribed methotrexate (51.62%; South Central
region).
Effective treatments for RA are available;8 21 however,
the results from our study demonstrate that RA is often
suboptimally treated and that regional variation in the
Table 1 Proportion of patients prescribed DMARDs within 12 months versus number diagnosed according to time period
across all regions
Time period
Number of patients
diagnosed with RA
Number of patients
prescribed DMARD
(%)
Number of patients
prescribed methotrexate
(%)
Number of patients
prescribed DMARD
combination (%)
1995–1999 1620 36.9 11.6 0.9
2000–2005 3411 46.1 23.6 3.5
2006–April 2010 3218 60.1 40.7 9.0
DMARD, disease-modifying antirheumatic drugs; RA, rheumatoid arthritis.
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management of RA persists after almost 2 years of guid-
ance being available. Despite a recommendation for
ﬁrst-line treatment with combination DMARDs, fewer
than 1 in 10 RA patients in the UK receive this therapy.
Although there has been an encouraging increase in
DMARD and methotrexate prescribing it is too early for
us to conclude with any accuracy whether the more
recently published NICE and EULAR guidelines have
inﬂuenced DMARD prescribing in the UK. Recently
published data indicate that the challenge of RA guide-
line implementation is not restricted to the UK.
Assessment of prescribing practices in a US cohort of
RA patients before and after the publication of ACR
treatment recommendations indicates that at best only
around 50% of RA patients with active disease receive
care consistent with the current recommendations.22
The longer-term impact of our ﬁndings should be
considered including the cost of surgical intervention
when RA is suboptimally controlled resulting in joint
damage. Policymakers should be aware of the persist-
ence of variation and assess how best to minimise
inequalities in RA care. A future challenge is how best to
disseminate and embed new standards of care into
routine clinical practice especially for chronic diseases
Figure 1 (A) Percentage of
patients prescribed
disease-modifying antirheumatic
drugs (DMARDs) at 12 months by
region for the time period 1995–
1999. (B) Percentage of patients
prescribed DMARDs at
12 months by region for the time
period 2000–2005.
(C) Percentage of patients
prescribed DMARDs at
12 months by region for the time
period 2006–2010.
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such as RA where treatment is undertaken by a range of
healthcare professionals in different settings. This is
likely to be ever more relevant as the care of patients
with chronic disease increasingly is being transferred
into the community setting.
We conclude that there is a need to optimise dissemin-
ation and implementation of high-quality clinical guide-
lines, that systems and processes for monitoring
implementation should be developed, and that relevant
indicators should be incorporated to ensure that guide-
lines are followed. Furthermore, accurate information
on current prescribing in RA is vital to inform the devel-
opment of the planned NICE Quality Standard for RA.
Strengths and weaknesses
One of the strengths of our study was the size of the
study population with 15 259 patients with incident RA
and of the long-term follow-up of these patients (mean
5.5 years but up to 15.3 years for some patients).
Another is the generalisability of the GPRD database
from which our data were obtained. The GPRD is repre-
sentative of patients and practices throughout the UK,23
and encompasses patients treated in primary, secondary
and tertiary care. The regional variation observed in pre-
scribing of DMARDs could be due to regional differ-
ences in the incidence of RA. However, data on age of
diagnosis over the duration of the study (appendix 3)
together with data (for 2009) on point prevalence and
incidence rates for RA in the GPRD (appendix 4) were
as expected, indicating robustness of the data.
The coding of the diagnosis of RA is a potential limita-
tion. However, GPRD has been validated in previous
studies12 and again in this study by the observation of
similar demographics for DMARD versus non-DMARD
users. Furthermore, practices are monitored for the
accuracy and completeness of data they submit to the
GPRD data by running set queries on the data and as
they are reimbursed by GPRD, penalties can be levied
against practices that routinely fail to meet recording
standards.23 It is also unlikely that our results are com-
promised by healthcare seeking behaviour given the
similar rates of prescribing of non-antirheumatic medica-
tion (statins, aspirin, antihypertensives and diabetic med-
ications) in the full RA cohort versus matched controls
(appendix 3). There may be temporal and regional vari-
ation in when GPs start to prescribe DMARDs. In some
areas the GP initiates the ﬁrst DMARD prescription on
the advice of the rheumatologist; in other areas the hos-
pital rheumatologist may initiate prescribing for a period
of time. However, by 12 months it seems likely that most
prescribing will be via the GP. This is supported by data
from the IMS British Pharmaceutical Index/IMS
Hospital Pharmacy Index which demonstrates that
across all indications, over 90% of all DMARDs prescrib-
ing is carried out within primary care; for methotrexate,
around 75–80% of all prescribing is carried out in the
primary care setting.24 We have recently performed a
survey of primary care trust in England that suggests
more than 90% of methotrexate prescribing is ultimately
performed in primary care with 77% by 6 months (per-
sonal communication submitted for publication).
Prescribing data for the use of DMARDs appears to be
strong in the GPRD. However, as biological therapies are
not usually prescribed by primary care we are unable to
comment on their use as the GPRD only contains very
limited information on their prescribing.
CONCLUSIONS
In summary, there has been a substantial improvement
in the treatment of RA across the UK over the 15-year
period from 1995 to 2010 with increasing use of
DMARDs which currently represent best clinical prac-
tice. Despite this improvement, RA remains under-
treated according to clinical recommendations and
guidelines in the UK10 and elsewhere.25 In addition,
regional variation in DMARD and methotrexate pre-
scribing persists across the UK.
Improvement in RA treatment is needed UK-wide:
identiﬁcation and assessment of models of RA treatment
that demonstrate implementation of evidence-based best
clinical practice would minimise variation, facilitate
nationally a uniform approach to RA treatment, to both
improve patient outcomes and optimise resource use.
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